Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 14.97M | 14.97M | 14.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 14.97M | 14.97M | 14.97M |
| Cost of Revenue | 133.00K | -172.00K | 530.00K | 1.04M | 1.68M |
| Gross Profit | -133.00K | 172.00K | 14.44M | 13.93M | 13.29M |
| SG&A Expenses | 34.67M | 29.80M | 38.45M | 30.27M | 23.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -548.00K | -1.29M | -1.22M | -1.78M | -1.76M |
| Total Operating Expenses | 57.69M | 54.48M | 68.58M | 64.20M | 60.12M |
| Operating Income | -57.69M | -54.48M | -53.62M | -49.23M | -45.15M |
| Income Before Tax | -66.63M | -76.06M | -69.55M | -65.35M | -61.23M |
| Income Tax Expenses | -175.00K | -115.00K | -47.00K | -29.00K | -44.00K |
| Earnings from Continuing Operations | -66.46 | -75.95 | -69.50 | -65.32 | -61.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 30.00K | 68.00K | 78.00K | 88.00K | 109.00K |
| Net Income | -66.43M | -75.88M | -69.43M | -65.23M | -61.07M |
| EBIT | -57.69M | -54.48M | -53.62M | -49.23M | -45.15M |
| EBITDA | -54.84M | -51.32M | -49.88M | -46.02M | -42.55M |
| EPS Basic | -1.64 | -1.88 | -1.73 | -1.64 | -1.55 |
| Normalized Basic EPS | -0.86 | -0.81 | -0.79 | -0.73 | -0.68 |
| EPS Diluted | -1.65 | -1.89 | -1.74 | -1.65 | -1.56 |
| Normalized Diluted EPS | -0.86 | -0.81 | -0.79 | -0.73 | -0.68 |
| Average Basic Shares Outstanding | 162.10M | 161.43M | 160.18M | 158.88M | 157.39M |
| Average Diluted Shares Outstanding | 162.10M | 161.43M | 160.18M | 158.88M | 157.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |